Google Chrome
Safari
Firefox
Edge
Press Release / Sep 19, 2024
Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
Search
Press Release / Aug 23, 2022
Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Article / Feb 23, 2026
Hovione’s Diane Villax: “I was not brought up to be a business woman”
Executiva, 23 February 2026
Press Release / Nov 29, 2023
Hovione expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
News / Sep 23, 2021
Hovione awarded with the COTEC INNOVATIVE 2021 statute
Innovation potential in profitable growth and financial strength
News / Sep 09, 2024
Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions
Hovione commitment to setting SBTs in line with the Paris Agreement
Press Release / Mar 17, 2021
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Press Release / Feb 25, 2022
Jean-Luc Herbeaux to become Hovione CEO
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022